Study Suggests Survival Advantage for Ovarian Cancer Patients with BRCA Mutations | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The five-year survival rate for individuals with invasive epithelial ovarian cancer is generally higher for women with mutations in BRCA1 or BRCA2 than it is for those without, according to a new study in the Journal of the American Medical Association.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.